Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence
8 affiliations
- 1Department of Physical Medicine and Rehabilitation, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- 2Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- 3Spine and Nerve Center of the Virginias, West Virginia University, Thomas Health Campus, Charleston, WV 25309, USA
- 4Albert Einstein College of Medicine, Bronx, NY 10461, USA
- 5Department of Anesthesiology, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA
- 6Department of Anesthesiology, The University of Kansas School of Medicine, Kansas City, MO 66160, USA
- 7Boomerang Healthcare, Walnut Creek, CA 94598, USA
- 8Division of Pain, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Abstract
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed from the amino-acid composition of epithalamin, a chemically distinct pineal-derived polypeptide preparation. This narrative review evaluates the mechanistic, preclinical, and human evidence for synthetic epitalon in the context of regenerative and longevity medicine, while considering epithalamin studies separately as historical context. PubMed and Google Scholar were searched through 22 September 2026, with primary experimental and clinical studies prioritized and evidence appraised by study design, model, sample size, intervention, outcomes, safety reporting, and independent replication. Epitalon has been reported to modulate telomere-maintenance pathways, circadian and neuroendocrine function, oxidative stress, and cellular aging markers. Preclinical studies suggest biological activity, but direct evidence in musculoskeletal disease models is lacking. Human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa; no adequately powered randomized trial has established therapeutic efficacy. Pharmacokinetic, dose-ranging, and long-term safety data remain inadequate, while oncologic, immunogenicity, product-quality, and regulatory uncertainties following a 2026 FDA advisory review remain unresolved. Epitalon is therefore biologically active but clinically unproven, and further standardized pharmacologic, safety, and disease-specific studies are needed before clinical translation.
Related
- Obesity and Oral Health: Clinical Associations, Mechanistic Evidence, and Implications for Dental Care—A Narrative Review
- From Active Compound to Target Epithelium: Local Delivery, Preclinical Model Validity, and Clinical Endpoint Interpretation in Topical Therapy for HPV-Associated Lower Genital Tract Disease—A Narrative Review
- Edible and Medicinal Mushrooms in Metabolic Syndrome: From Mechanistic Plausibility to Clinical Evidence—A Narrative Review
- Evaluating Acupuncture for Chemotherapy-Induced Peripheral Neuropathic Pain: A Narrative Review of Clinical Evidence and Mechanistic Perspectives
- Clinical Evaluation of Biased μ-Opioid Receptor Agonists: A Narrative Comparative Review from Oliceridine to Tegileridine and Mechanistic Reappraisal.
BibTeX
@article{jain2026epitalon,
title = {{Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence}},
author = {Ankur Jain and David M. Gallacher and Mohammed A. Issa and Timothy R. Deer and Robert J. Yong and Sudhir Diwan and Woojin Lee and Dawood Sayed and Kasra Amirdelfan and Christopher L. Robinson},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27198922},
url = {https://www.mdpi.com/1422-0067/27/19/8922},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence
AU - Ankur Jain
AU - David M. Gallacher
AU - Mohammed A. Issa
AU - Timothy R. Deer
AU - Robert J. Yong
AU - Sudhir Diwan
AU - Woojin Lee
AU - Dawood Sayed
AU - Kasra Amirdelfan
AU - Christopher L. Robinson
PY - 2026
DA - 2026/10/08
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27198922
UR - https://www.mdpi.com/1422-0067/27/19/8922
AB - Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed from the amino-acid composition of epithalamin, a chemically distinct pineal-derived polypeptide preparation. This narrative review evaluates the mechanistic, preclinical, and human evidence for synthetic epitalon in the context of regenerative and longevity medicine, while considering epithalamin studies separately as historical context. PubMed and Google Scholar were searched through 22 September 2026, with primary experimental and clinical studies prioritized and evidence appraised by study design, model, sample size, intervention, outcomes, safety reporting, and independent replication. Epitalon has been reported to modulate telomere-maintenance pathways, circadian and neuroendocrine function, oxidative stress, and cellular aging markers. Preclinical studies suggest biological activity, but direct evidence in musculoskeletal disease models is lacking. Human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa; no adequately powered randomized trial has established therapeutic efficacy. Pharmacokinetic, dose-ranging, and long-term safety data remain inadequate, while oncologic, immunogenicity, product-quality, and regulatory uncertainties following a 2026 FDA advisory review remain unresolved. Epitalon is therefore biologically active but clinically unproven, and further standardized pharmacologic, safety, and disease-specific studies are needed before clinical translation.
SN - 1422-0067
ER -